Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL25209026 | 0.89 | GAA (0.33) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL4696166 | 0.86 | MAPT (0.39) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL12571540 | 0.86 | MAPT (0.39) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL4407526 | 0.86 | MAPT (0.39) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL27359008 | 0.84 | GAA (0.35) | GAAMGAMSIMGAM2KMT2A | |
| Hydrochloric Acid SCHEMBL29927379 | 0.84 | MAPT (0.41) | GAAMGAMSIMGAM2KMT2A | |
| Hydrochloric Acid SCHEMBL23294651 | 0.84 | MAPT (0.41) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL13775379 | 0.83 | KMT2A (0.40) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL1970713 | 0.83 | KMT2A (0.40) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL31722366 | 0.82 | NAAA (0.42) | ALDH1A1TSHREPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281116-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4433471-A1 | N-(2H-INDAZOL-5-YL)PYRAZINE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS HTT MODULATORS FOR THE TREATMENT OF HUNTINGTON'S DISEASE | CHDI Foundation, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| WO-2024001839-A1 | HETEROAROMATIC RING COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-01-04 | — | — | WO | disclosed |
| CN-110520422-B | Novel pyridonecarboxylic acid derivative or salt thereof | 涌永制药株式会社 | 2023-09-05 | — | — | CN | disclosed |
| US-20230159531-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159531-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023091456-A1 | N-(2H-INDAZOL-5-YL)PYRAZINE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS HTT MODULATORS FOR THE TREATMENT OF HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230159531-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023091456-A1 | N-(2H-INDAZOL-5-YL)PYRAZINE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS HTT MODULATORS FOR THE TREATMENT OF HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-11286255-B2 | Pyridone carboxylic acid derivative or salt thereof | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-29 | — | — | US | disclosed |
| EP-3957633-A1 | A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF | Hinova Pharmaceuticals Inc. (CN) | 2022-02-23 | — | — | EP | disclosed |
| WO-2020211822-A1 | A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF | 成都海创药业有限公司 | 2020-10-22 | — | — | WO | disclosed |
| US-20200062752-A1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2020-02-27 | — | — | US | disclosed |
| EP-3535265-A2 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| WO-2018102067-A2 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-5532255-A | Adhesion receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1996-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281116-B2 | HTT modulators for treating Huntington's disease | HTT, HYPK, ATXN2 | GAA 143/4885MGAM 3957/4885SI 4697/4885 |
| US-20230159531-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | GAA 143/4885MGAM 3957/4885SI 4697/4885 |
| US-20200062752-A1 | NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | RAB10, HDAC10, NEK10 | GAA 4620/4885MGAM 4797/4885SI 4850/4885 |
| US-11286255-B2 | Pyridone carboxylic acid derivative or salt thereof | RARA, RAB10, RABL6 | GAA 4477/4885MGAM 4778/4885SI 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.